Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the completion of a Series C+ financing round worth RMB 100 million ($13.8 million). The round was led by Oriza Holdings, with significant contributions from YZ Capital, JianSu Capital, Leader Venture Capital, and returning investor RealHarmony Capital. This capital influx will accelerate the commercialization of SmartNuclide’s innovative pipeline, including its human thyrotropin (rhTSH) ZhiShuJia, and expand its presence in the radiopharmaceutical market.
ZhiShuJia, developed by SmartNuclide, is poised to become the first rhTSH injection for radioactive iodine therapy in thyroid cancer in China, and it is nearing regulatory approval. The company plans to utilize the funds to support clinical studies for its innovative radioactive diagnostic drugs, such as SNA002, and IND filings for new therapeutic radiopharmaceuticals with novel targets like SNA014 and SNA025. Additionally, the capital will be directed towards the construction of the “Smart” series radioactive drug development platform, reinforcing SmartNuclide’s commitment to advancing nuclear medicine.
SmartNuclide’s focus on liver and extrahepatic organs highlights the company’s expertise in applying small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to manipulate gene expression within cells, offering potential treatments for a wide range of diseases. With no similar drug having entered the clinical stage globally, SmartNuclide is at the forefront of radiopharmaceutical innovation.- Flcube.com
